HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells.

Abstract
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. It is unknown whether β-1,3;1,6-glucan can induce immune suppressive effects. Here, we study intestinal anti-inflammatory activity of Lentinula edodes-derived β-1,3;1,6-glucan, which is known as lentinan. Dextran sulfate sodium (DSS)-induced colitis mice were used to elucidate effects of lentinan in vivo. In the cellular level assessment, lentinan was added into a co-culture model consisting of intestinal epithelial Caco-2 cells and LPS-stimulated macrophage RAW264.7 cells. Ligated intestinal loop assay was performed for assessing effects of lentinan on intestinal epithelial cells (IECs) in vivo. Oral administration of lentinan (100 µg/mouse) significantly ameliorated DSS-induced colitis in body weight loss, shortening of colon lengths, histological score, and inflammatory cytokine mRNA expression in inflamed tissues. Lentinan reduced interleukin (IL)-8 mRNA expression and nuclear factor (NF)-κB activation in Caco-2 cells without decreasing of tumor necrosis factor (TNF)-α production from RAW264.7 cells. Flow cytometric analysis revealed that surface levels of TNF receptor (TNFR) 1 were decreased by lentinan treatment. A clathrin-mediated endocytosis inhibitor, monodansylcadaverine, canceled lentinan inhibition of IL-8 mRNA expression. Moreover, lentinan inhibited TNFR1 expression in Caco-2 cells in both protein and mRNA level. Lentinan also inhibited TNFR1 mRNA expression in mouse IECs. These results suggest that lentinan exhibits intestinal anti-inflammatory activity through inhibition of IL-8 mRNA expression associated with the inhibition of NF-κB activation which is triggered by TNFR1 endocytosis and lowering of their expression in IECs. Lentinan may be effective for the treatment of gut inflammation including IBD.
AuthorsYosuke Nishitani, Ling Zhang, Masaru Yoshida, Takeshi Azuma, Kazuki Kanazawa, Takashi Hashimoto, Masashi Mizuno
JournalPloS one (PLoS One) Vol. 8 Issue 4 Pg. e62441 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID23630633 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Cytokines
  • Interleukin-8
  • Lipopolysaccharides
  • RELA protein, human
  • RNA, Messenger
  • Receptors, Tumor Necrosis Factor, Type I
  • Transcription Factor RelA
  • Cytochalasin D
  • Lentinan
Topics
  • Animals
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Caco-2 Cells
  • Cell Nucleus (metabolism)
  • Coculture Techniques
  • Colitis (drug therapy, immunology, metabolism)
  • Colon (drug effects, metabolism, pathology)
  • Cytochalasin D (pharmacology)
  • Cytokines (genetics, metabolism)
  • Endocytosis (drug effects)
  • Epithelial Cells (drug effects, immunology, metabolism)
  • Gene Expression (drug effects)
  • Humans
  • Interleukin-8 (genetics, metabolism)
  • Intestinal Mucosa (drug effects, immunology, metabolism)
  • Lentinan (pharmacology, therapeutic use)
  • Lipopolysaccharides (pharmacology)
  • Mice
  • Protein Transport
  • RNA, Messenger (genetics, metabolism)
  • Receptors, Tumor Necrosis Factor, Type I (genetics, metabolism)
  • Transcription Factor RelA (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: